Association of Cytochrome P450 2C9*3 and Angiotensin II Receptor 1 (1166A>C) Gene Polymorphisms With the Antihypertensive Effect of Irbesartan

Abstract Background To analyze whether the cytochrome P450 enzyme 2C9*3 (CYP2C9*3) and angiotensin II receptor 1 (AGTR1) (1166A>C) gene polymorphisms are associated with risk of essential hypertension (EH) antihypertensive effect irbesartan. Methods A total 2,057 EH patients 286 healthy controls were enrolled for genotyping in which 598 given irbesartan 150 mg/day 4 weeks. Blood pressure all subjects determined before at end 4-week treatment. Results There was no significant difference genotype frequencies CYP2C9*3 AGTR1 between control groups. Subjects *1*3/*3*3 genotypes had larger systolic diastolic blood reductions (34.9 ± 15.5 vs. 29.3 10.2 mm Hg 22.8 9.0 19.6 8.5 Hg, respectively) compared *1*1 genotype. For polymorphisms, although there among AC, CC, AA genotypes, male AC/CC (32.3 1.3 0.5 21.6 0.8 19.4 0.1 respectively, P < 0.05) response to treatment Conclusions Polymorphisms not significantly different controls. Male AC CC show better than